供者淋巴细胞输注预防单倍型造血干细胞移植后白血病复发的回顾性分析

 目的　观察供者淋巴细胞输注（DLI）对单倍型造血干细胞移植（HSCT）后白血病复发的预防作用，评价其疗效及安全性。方法　对20例白血病患者在单倍型HSCT后进行预防性DLI，观察移植物抗宿主病（GVHD）的发生及长期生存情况。结果　随访25（4～60）个月，20例患者中有11例长期生存，生存率为55 %；9例复发死亡；19例患者在接受DLI后出现不同程度的急性GVHD（aGVHD），其中Ⅲ度以上4例，累积发生率22.9 %。结论　DLI可预防单倍型HSCT后白血病复发，效果显著，安全性较好。

Retrospective analysis of donor lymphocyte infusion for preventing relapse of leukemia after haplotype hematopoietic stem cell transplantation

Objective To investigate the effect of donor lymphocyte infusion （DLI） for preventing relapse of leukemia after haplotype bematopoietic stem cell transplantation （HSCT）, and evaluate the therapeutic effect and the safety of DLI. Methods The 20 haplotype HSCT patients who received DLI were studied for the occurrence of graft-versus-host disease （GVHD） and long-term survival. Results Eleven of twenty patients survived leukemia-free for a median of 25（4-60） months, and leukemia-free survival rate was 55 %. 9 cases died of relapse. 19 patients occurred acute GEHD （aGVHD） after received DLI, 4 of them were severe. Conclusion The prophylactic DLI is effective for preventing from relapse of leukemia. It might be feasible option.